Crown Bioscience Opens New Model Development Center in Kannapolis, North Carolina

What's Happening?

Crown Bioscience, a global contract research organization, has expanded its U.S. presence by opening a new model development center in Kannapolis, North Carolina. This facility is designed to enhance Crown Bioscience's capabilities in delivering advanced preclinical oncology models, including patient-derived xenografts and organoids. The center aims to support the evolving needs of pharmaceutical and biotechnology companies by providing localized access to global scientific expertise and top-quality preclinical services. The facility will focus on advancing clinically relevant oncology models and accelerating the adoption of 3D cell culture and organoid technologies.

Why It's Important?

The opening of the new center in Kannapolis is a strategic move by Crown Bioscience to strengthen its U.S. operations and meet the growing demand for innovative oncology models. This expansion is significant for the local economy, as it will create new job opportunities and attract scientific expertise to the region. The facility's focus on advanced oncology models aligns with industry trends towards precision medicine and regulatory changes, such as the FDA Modernization Act 2.0. Crown Bioscience's investment in this center underscores its commitment to supporting drug development and research in the U.S.

What's Next?

Once fully operational, the Kannapolis site is expected to broaden its service capabilities, creating new opportunities for local talent and contributing to the local economy through job creation and training initiatives. Crown Bioscience will likely continue to expand its model platform portfolio and collaborate with other facilities to enhance its offerings. The company may also explore further investments in similar facilities to strengthen its global presence and support the next generation of oncology research.